Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.

<h4>Background</h4>Vitamin K-antagonists (VKA) are treatment of choice and standard care for patients with venous thrombosis and thromboembolic risk. In experimental animal models as well as humans, VKA have been shown to promote medial elastocalcinosis. As vascular calcification is cons...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Leon J Schurgers, Ivo A Joosen, Eduard M Laufer, Martijn L L Chatrou, Marjolein Herfs, Mark H M Winkens, Ralf Westenfeld, Verena Veulemans, Thilo Krueger, Catherine M Shanahan, Willi Jahnen-Dechent, Erik Biessen, Jagat Narula, Cees Vermeer, Leonard Hofstra, Chris P Reutelingsperger
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/073113b23a7543c09f9b7724adf5511a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:073113b23a7543c09f9b7724adf5511a
record_format dspace
spelling oai:doaj.org-article:073113b23a7543c09f9b7724adf5511a2021-11-18T07:07:12ZVitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.1932-620310.1371/journal.pone.0043229https://doaj.org/article/073113b23a7543c09f9b7724adf5511a2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22952653/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Vitamin K-antagonists (VKA) are treatment of choice and standard care for patients with venous thrombosis and thromboembolic risk. In experimental animal models as well as humans, VKA have been shown to promote medial elastocalcinosis. As vascular calcification is considered an independent risk factor for plaque instability, we here investigated the effect of VKA on coronary calcification in patients and on calcification of atherosclerotic plaques in the ApoE(-/-) model of atherosclerosis.<h4>Methodology/principal findings</h4>A total of 266 patients (133 VKA users and 133 gender and Framingham Risk Score matched non-VKA users) underwent 64-slice MDCT to assess the degree of coronary artery disease (CAD). VKA-users developed significantly more calcified coronary plaques as compared to non-VKA users. ApoE(-/-) mice (10 weeks) received a Western type diet (WTD) for 12 weeks, after which mice were fed a WTD supplemented with vitamin K(1) (VK(1), 1.5 mg/g) or vitamin K(1) and warfarin (VK(1)&W; 1.5 mg/g & 3.0 mg/g) for 1 or 4 weeks, after which mice were sacrificed. Warfarin significantly increased frequency and extent of vascular calcification. Also, plaque calcification comprised microcalcification of the intimal layer. Furthermore, warfarin treatment decreased plaque expression of calcification regulatory protein carboxylated matrix Gla-protein, increased apoptosis and, surprisingly outward plaque remodeling, without affecting overall plaque burden.<h4>Conclusions/significance</h4>VKA use is associated with coronary artery plaque calcification in patients with suspected CAD and causes changes in plaque morphology with features of plaque vulnerability in ApoE(-/-) mice. Our findings underscore the need for alternative anticoagulants that do not interfere with the vitamin K cycle.Leon J SchurgersIvo A JoosenEduard M LauferMartijn L L ChatrouMarjolein HerfsMark H M WinkensRalf WestenfeldVerena VeulemansThilo KruegerCatherine M ShanahanWilli Jahnen-DechentErik BiessenJagat NarulaCees VermeerLeonard HofstraChris P ReutelingspergerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 8, p e43229 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Leon J Schurgers
Ivo A Joosen
Eduard M Laufer
Martijn L L Chatrou
Marjolein Herfs
Mark H M Winkens
Ralf Westenfeld
Verena Veulemans
Thilo Krueger
Catherine M Shanahan
Willi Jahnen-Dechent
Erik Biessen
Jagat Narula
Cees Vermeer
Leonard Hofstra
Chris P Reutelingsperger
Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
description <h4>Background</h4>Vitamin K-antagonists (VKA) are treatment of choice and standard care for patients with venous thrombosis and thromboembolic risk. In experimental animal models as well as humans, VKA have been shown to promote medial elastocalcinosis. As vascular calcification is considered an independent risk factor for plaque instability, we here investigated the effect of VKA on coronary calcification in patients and on calcification of atherosclerotic plaques in the ApoE(-/-) model of atherosclerosis.<h4>Methodology/principal findings</h4>A total of 266 patients (133 VKA users and 133 gender and Framingham Risk Score matched non-VKA users) underwent 64-slice MDCT to assess the degree of coronary artery disease (CAD). VKA-users developed significantly more calcified coronary plaques as compared to non-VKA users. ApoE(-/-) mice (10 weeks) received a Western type diet (WTD) for 12 weeks, after which mice were fed a WTD supplemented with vitamin K(1) (VK(1), 1.5 mg/g) or vitamin K(1) and warfarin (VK(1)&W; 1.5 mg/g & 3.0 mg/g) for 1 or 4 weeks, after which mice were sacrificed. Warfarin significantly increased frequency and extent of vascular calcification. Also, plaque calcification comprised microcalcification of the intimal layer. Furthermore, warfarin treatment decreased plaque expression of calcification regulatory protein carboxylated matrix Gla-protein, increased apoptosis and, surprisingly outward plaque remodeling, without affecting overall plaque burden.<h4>Conclusions/significance</h4>VKA use is associated with coronary artery plaque calcification in patients with suspected CAD and causes changes in plaque morphology with features of plaque vulnerability in ApoE(-/-) mice. Our findings underscore the need for alternative anticoagulants that do not interfere with the vitamin K cycle.
format article
author Leon J Schurgers
Ivo A Joosen
Eduard M Laufer
Martijn L L Chatrou
Marjolein Herfs
Mark H M Winkens
Ralf Westenfeld
Verena Veulemans
Thilo Krueger
Catherine M Shanahan
Willi Jahnen-Dechent
Erik Biessen
Jagat Narula
Cees Vermeer
Leonard Hofstra
Chris P Reutelingsperger
author_facet Leon J Schurgers
Ivo A Joosen
Eduard M Laufer
Martijn L L Chatrou
Marjolein Herfs
Mark H M Winkens
Ralf Westenfeld
Verena Veulemans
Thilo Krueger
Catherine M Shanahan
Willi Jahnen-Dechent
Erik Biessen
Jagat Narula
Cees Vermeer
Leonard Hofstra
Chris P Reutelingsperger
author_sort Leon J Schurgers
title Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
title_short Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
title_full Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
title_fullStr Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
title_full_unstemmed Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
title_sort vitamin k-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
publisher Public Library of Science (PLoS)
publishDate 2012
url https://doaj.org/article/073113b23a7543c09f9b7724adf5511a
work_keys_str_mv AT leonjschurgers vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT ivoajoosen vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT eduardmlaufer vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT martijnllchatrou vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT marjoleinherfs vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT markhmwinkens vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT ralfwestenfeld vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT verenaveulemans vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT thilokrueger vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT catherinemshanahan vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT willijahnendechent vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT erikbiessen vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT jagatnarula vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT ceesvermeer vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT leonardhofstra vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
AT chrispreutelingsperger vitaminkantagonistsaccelerateatheroscleroticcalcificationandinduceavulnerableplaquephenotype
_version_ 1718423894920003584